Jeevan Scientific Technology Limited recently announced the successful completion of a Remote Interactive Evaluation (RIE) conducted by the United States Food and Drug Administration (US FDA). The evaluation, which took place from October 17, 2025 to November 6, 2025, focused on the company's Clinical Pharmacology facility.

Evaluation Scope and Outcome

The US FDA's evaluation encompassed several key areas:

• BA/BE studies
• Operations
• Systems
• Procedures

Notably, the RIE concluded with no critical observations, marking a significant achievement for Jeevan Scientific Technology.

Implications for the Company

The successful completion of this evaluation without any critical observations is a positive development for Jeevan Scientific Technology. It demonstrates the company's commitment to maintaining high standards in its clinical pharmacology operations and adherence to regulatory requirements.

This outcome may potentially:

• Enhance the company's credibility in the pharmaceutical research sector
• Strengthen its position for future collaborations or contracts
• Provide reassurance to stakeholders about the quality of the company's operations

It's important to note that this evaluation is a routine part of regulatory oversight in the pharmaceutical industry. The company will likely continue to be subject to periodic evaluations to ensure ongoing compliance with FDA standards.

Stakeholders may view this development as part of Jeevan Scientific Technology's ongoing efforts to maintain regulatory compliance and operational excellence in its field of clinical pharmacology research.

Jeevan Scientific Technology Limited (JSTL) has announced plans to raise Rs 30.74 crore through a preferential issue of convertible warrants and equity shares. The company's board has approved the issuance of 35 lakh convertible warrants and 41.85 lakh equity shares to promoters and non-promoters, as per a notice for an Extraordinary General Meeting (EGM) scheduled for November 12, 2025.

Capital Restructuring Details

• JSTL plans to increase its authorized share capital from Rs 21.00 crore to Rs 25.00 crore.
• The company will issue 35 lakh convertible warrants at Rs 40.00 per warrant to promoters and non-promoters, raising Rs 14.00 crore.
• Additionally, 41.85 lakh equity shares will be issued at Rs 40.00 per share to non-promoters, raising Rs 16.74 crore.
• The total fundraising amounts to Rs 30.74 crore.

Utilization of Funds

The company intends to use the raised capital for the following purposes:

Key Points of the Preferential Issue

• The issue price of Rs 40.00 per share includes a premium of Rs 30.00 over the face value of Rs 10.00.
• The relevant date for pricing is October 13, 2025.
• Warrants will be convertible into equity shares within 18 months from the date of allotment.
• The preferential issue is subject to shareholder approval at the EGM.

Additional Corporate Actions

JSTL also plans to:

• Adopt a new Memorandum of Association under the Companies Act 2013.
• Change its registered office state from Andhra Pradesh to Telangana.

Voting and Participation Details

• The EGM will be held through Video Conference / Other Audio-Visual Means.
• The cut-off date for e-voting is November 5, 2025.
• Shareholders can join the EGM 15 minutes before and after the scheduled time.

This capital restructuring move by Jeevan Scientific Technology Limited aims to strengthen its financial position and support long-term growth initiatives. Shareholders will have the opportunity to vote on these proposals at the upcoming EGM.